The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1591-1599

  Lamas, M J ^a   Duran, G ^a   Balboa, E ^b   Bernardez, B ^a   Candamio, S ^a   Vidal, Y ^a   Mosquera, A ^a   Giraldez, J M ^a   Lopez, R ^a   Carracedo, A ^b,c   Barros, F ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Colorectal cancer; Irinotecan; Pharmacogenetic; Polymorphisms; Toxicity

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOXICITY; FEBRILE NEUTROPENIA; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; UGT1A GENE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC;

EID: 84863805445     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1866-2     Document Type: Article

References (31)

1. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, Gramont A (2009) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229-237
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinava F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
3. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer P, Mitchell E, Alberts S, Schwartz M, Benson Al B (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg h, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
6. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang C, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh J, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417
7. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J,Cohn A, Shahin S, Griffin T (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) ± panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Proceedings of 2008 Gastrointestinal Cancers Symposium (Abstr 273). Orlando, FL.Abstract available on http://www.asco.org.
8. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
9. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47
10. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388
11. Côté JF,Kirzin S,KramarA,Mosnier JF,DieboldMD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, YchouM(2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275
12. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159
13. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R, Leon A (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007-1016
14. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682
15. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290-1295
16. Zhe-Yi H, Qi Y, Pei Q, Guo C (2010) Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk. Clin Cancer Res 16(15):3832-3842
17. Hu ZY, Yu Q, Zhao YS (2010) Dose-dependent association between UGT1A1 *28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 46:1856-1865
18. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ (2005) Haplotypes of variants in the UDP glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 15:295-301
19. Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro- Muñoz C, Lopez R, Carracedo A, Barros F (2010) Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 11(6):747-761
20. Cecchin E, Innocenti F, D ́ Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7 and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin and irinotecan. J Clin Oncol 27:2457-2465
21. Innocenti F, Grimsley C, Das S, Ramírez J, Cheng C, Kuttab- Boulos H, Ratain MJ, Di Rienzo A (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733
22. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27:2604-2614
23. Nagar S, Blanchard RL (2006) Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT)1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393-409
24. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F (2010) Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/ leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 28:866-871
25. Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M (2011) A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 105:53-57
26. Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B, Rana-Diez P, Lopez R, Carracedo A, Barros F (2012) X-ray cross complementing group 1 (XRCC1) and Thymidylate Synthase polymorphismsmay predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 82(1):138-144
27. Martinez-Balibrea E, Adad A, Martinez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103:581-589
28. Carlini LE, Merolop NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphism predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Canc Res 11:1226-1236
29. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Igbal S, Lenz HJ, Ladner RD (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319-327
30. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G, Villanueva A (2006) Tumor thymidylate synthase 1494del6 Genotype As a Prognostic factor in colorectal cancer patients receiving fluorouracil- based adjuvant treatment. J Clin Oncol 24:1603-1611
31. Artac M, Hakan B, Pehlivan S, Akcan S, Pehlivan M, Sever T, Ozdogan M, Savas B (2010) The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J Cancer Res Clin Oncol 136:803-809